Additional secondary outcomes assessed included serum lipids , laboratory biomarkers of inflammation ( C-reactive protein and interleukin 6 ) and oxidative stress ( plasma F2 isoprostanes and isofurans ) , monocyte cytokine production , and predialysis blood pressure .